Markets steady after a violent week. Wall Street rebounded Monday — chip stocks posted their best day in a year and Nvidia’s chief called the rout a buying opportunity — lifting the S&P back to 7,435 (+0.70%) and the Nasdaq to 26,069 (+1.40%), with Asia following firmer. The Iran–Israel flare-up that reignited Monday (the war’s 101st day) was halted by evening at Trump’s urging, easing Brent back from a spike above $97 · Apple unveiled “Siri AI” at Monday’s WWDC keynote · Intesa launched a €30.6bn bid for Monte dei Paschi, reopening Italian bank M&A · but the rates drumbeat turns hawkish (Fed-hike talk) and private-credit redemptions keep a crack open under the tape.
Levels below are the Bloomberg Europe “Top Securities” ticker read at ~06:00 Rome. With US cash shut pre-open, the index prints are Monday’s closing levels — the session that rebounded after Friday’s chip rout (semis’ best day in a year; Nvidia “buy the dip”). The fresh move is in Asia, trading firmer this morning as Wall Street’s bounce carries over and the Iran–Israel flare-up cools. The week’s swing events are ahead: the SpaceX order book closes Wednesday, US May CPI is due, and the FOMC (16–17 June) lands into rising rate-hike chatter.
Top of the morning
Wall Street rebounds — chips’ best day in a year, Nvidia calls the rout a buy
After Friday’s AI-chip sell-off and a sharp Kospi-led plunge across Asia on Monday, US stocks turned up: the S&P closed +0.70% and the Nasdaq +1.40%, with semiconductors set for their best session in a year. Nvidia’s chief framed the tech selloff as a buying opportunity, and Intel rose on a report that Google will use it to make chips. The bounce is real but partial — it comes off a lower base, with firmer rates and private-credit stress the things that could cap it.
Iran–Israel flare-up halted by evening; oil gives back its spike
The conflict’s 101st day reignited: Iran and Israel exchanged strikes overnight Monday — the first since the early-April ceasefire — sending Brent above $97 intraday. By Monday afternoon Iran signalled a halt and Israel refrained at Trump’s request, with Netanyahu accepting; both warn they are ready to resume. Lebanon is the wedge — Tehran ties any restart to Israeli strikes on Hezbollah. Oil eased back (WTI ~$91), gold steady. The Strait of Hormuz stays shut for nearly 100 days; watch for a “flood of oil” if it reopens.
Apple unveils “Siri AI” at WWDC; investors weigh the payoff
At Monday’s WWDC keynote Apple rebranded its assistant as “Siri AI” — a more conversational, screen-aware system — alongside iOS 27 and across-the-board OS updates. The catch for the stock: the full Siri AI rollout slips to a beta later this year, with most features landing in the autumn. The question for holders is whether the overhaul can power the next leg in a soft phone and PC market.
Intesa’s €30.6bn Monte dei Paschi bid reopens Italian bank M&A
Intesa Sanpaolo launched a €30.6bn offer for Monte dei Paschi, likely triggering a fresh phase of Italian financial dealmaking; Rome says it won’t take sides — “it’s all about the money.” Separately, Tate & Lyle accepted a bid from Ingredion, another loss for London. A domestic angle worth watching for the Italian reader.
The IPO supply wave builds: SpaceX oversubscribed, OpenAI files
SpaceX’s listing is well oversubscribed with orders closing Wednesday, and OpenAI has filed confidentially for an IPO that could value it above $1tn. Strategists (Rob Arnott) warn mega-cap floats will weigh on other stocks for years by widening the gap between index giants and everyone else — a liquidity-absorption test as cash piles up, with a record ~$8tn parked in money-market funds.
Citadel Securities sees a risk the Fed is forced to raise rates soon; BMO calls the dollar the best bet in a “new regime of high rates”; and economists warn the ECB risks repeating a 2011 mistake if it hikes. The US 10-year sits at 4.55%, and an NY Fed survey shows job-seekers turning gloomier. Beneath the tape, a Blue Owl fund hit by redemptions is selling a $500m bond and retail money is edging out of private credit — the clearest persistent crack into this week’s CPI and the 16–17 June FOMC.
Pharma dealmaking is hot: GSK is in talks to buy cancer biotech Nuvalent for more than $9bn, on the heels of Incyte’s ~$2bn move for Star. AstraZeneca is advancing a weight-loss pill aimed at obesity leaders Novo Nordisk and Eli Lilly, just as Bloomberg notes Lilly’s ~30% weight-loss data sets a high bar. On biosecurity, a Big Take argues funding cuts have left the world exposed to a fast-spreading Ebola strain with no known treatment — a direct tie to this week’s clinical desk.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. Monday’s tape was a rebound — chips’ best day in a year, Nvidia calling the selloff a buy — but it sits on a two-sided base. The counterweights the dashboard tracks are all live: an oil overhang (the Iran–Israel flare-up spiked Brent above $97 before Iran’s halt pulled it back; Hormuz still shut ~100 days), a firmer-rates backdrop (Citadel flags possible Fed hikes, BMO’s “high-rates regime,” ECB hike risk; 10y 4.55%), and a persistent private-credit crack (a Blue Owl fund hit by redemptions, retail edging out, a record ~$8tn parked in money-market funds). War-chest deployment rules stay dormant — geopolitics is de-escalating and equities are bouncing, so this is a regime to respect, not a severe trigger. The single-name flow today is unusually rich and skews to your shelf.
Caterpillar (shelf single-name — the standout). FT’s “picks and shovels” piece puts Caterpillar among the once-staid industrials lifted by the data-centre scramble — a clean, positive AI-capex read on a direct holding. The buildout is now flowing into the physical layer (gensets, earthmoving, construction), not just chips.
Novo Nordisk & Eli Lilly (shelf — GLP-1). AstraZeneca is advancing a weight-loss pill aimed squarely at the obesity leaders — a competitive-threat signal for both your GLP-1 names — while Bloomberg’s parallel note that Lilly’s ~30% weight-loss data “sets a high bar” cuts the other way. Net: the oral-obesity race is intensifying; watch the read-through to pricing and share.
Pharma M&A (theme — Vertex / Thermo Fisher corner). GSK is in talks to buy cancer biotech Nuvalent for >$9bn, on the heels of Incyte’s ~$2bn move for Star — mid- and large-cap drugmakers are paying up to refill pipelines, a supportive backdrop for the biotech-adjacent shelf. No direct Vertex single-name alert in the window.
AI capex / IPO supply (theme & regime — Microsoft, Alphabet, Amazon, Broadcom, ASML). OpenAI’s confidential IPO filing (>$1tn) and SpaceX’s oversubscribed book (closing Wed) pile more equity supply onto the same AI dollars — a liquidity test for the mega-cap shelf, and a direct read-through to Microsoft as an OpenAI backer. Data-centre demand stays the structural tailwind (see Caterpillar).
Payments (theme — Visa / Mastercard). Only tangential alerts today: FT on African mobile-payments fintechs, plus Mastercard boosting Pride-month spending despite backlash. No core single-name catalyst.
Shelf single-names live today:Caterpillar (positive AI-capex), Novo Nordisk & Eli Lilly (competitive threat from AstraZeneca’s pill), and Microsoft (OpenAI-IPO read-through). Pharma M&A (GSK/Nuvalent, Incyte) and the AI-capex/IPO-supply theme round it out. (Name-level alerts surface here once FT routes them to this Gmail — see the iCloud→Gmail forwarding note if they stay sparse.)
Net: a relief rebound led by chips, with the Iran flare-up cooling and oil giving back its spike — but hawkish-rates chatter and private-credit redemptions keep the tone two-sided. Today’s shelf flow is constructive (Caterpillar AI-capex; pharma M&A) with one watch-item (AstraZeneca’s obesity pill vs Novo / Lilly). Regime: cautious rebound, not deploy — watch rates, credit and the ceasefire’s durability.
Markets snapshot
Bloomberg Europe “Top Securities” ticker, read ~06:00 Rome Tuesday. US cash is shut pre-open, so the index prints are Monday’s closing levels — the session that rebounded after Friday’s chip rout. Asia is trading firmer this morning as the bounce carries over; daily % shown is Monday’s session.
Instrument
Last (Mon close)
Change / context
S&P 500
7,435.49
+0.70% Mon · rebound; semis’ best day in a year
Nasdaq
26,069.08
+1.40% Mon · Nvidia “buy the dip,” Intel/Google
Bloomberg 500
2,689.13
+0.76% Mon
FTSE 100
10,373.20
+0.05% Mon · little changed
US 10-year Treasury
4.55%
yields firm · Fed-hike chatter returns
EUR/USD
~1.15
steady pre-open
GBP/USD
~1.33
broadly steady
Crude Oil (WTI)
$91.28
+0.8% · off Monday’s >$97 Brent spike as Iran halts
Gold (spot)
$4,367.50
+0.05% · holds; haven bid eases as risk steadies
Figures transcribed from the Bloomberg Europe “Top Securities” ticker; pre-open on Tuesday these remain Monday’s cash close. Equity direction is Monday’s rebound (semis’ best day in a year, Nvidia’s “buying opportunity” call). Brent jumped above $97 on Monday’s Iran–Israel exchange before easing as Iran signalled a halt; the WTI and gold prints read from the Bloomberg ticker.
Global markets & macro
After a brutal stretch — Friday’s Broadcom-led AI-chip rout, then a Kospi-led plunge across Asia on Monday — Wall Street found a floor. US stocks rebounded Monday (S&P +0.70%, Nasdaq +1.40%), with semiconductors set for their best day in a year; Nvidia’s chief publicly called the tech selloff a buying opportunity, and Intel jumped on a report that Google will use it to make chips. The AI-financing machine kept building through the wobble: SpaceX’s IPO is well oversubscribed with orders closing Wednesday, OpenAI filed confidentially for a listing that could top $1tn, and “a data center is a bank” has become Wall Street shorthand for how the buildout is being financed. TSMC’s standing warning that supply won’t meet AI demand for years frames the paradox — structural demand intact, valuations stretched and freshly tested.
Rates are the firmer, quieter story, and the one that could cap the bounce. Citadel Securities sees a risk the Fed is forced to raise rates soon; BMO calls the dollar the best bet in a “new regime of high rates”; even the ECB is warned against repeating a 2011 hiking mistake — all of which holds the US 10-year at 4.55%. An NY Fed survey showed job-seekers turning more pessimistic, a softer-labour signal cutting against the inflation worry. Beneath the tape, the clearest crack is private credit: a Blue Owl fund was hit by redemptions and is selling a $500m bond, retail investors are eyeing the exits, and a record ~$8tn now sits in money-market funds as savers wait out the uncertainty. FX was quiet — the euro near 1.15, sterling around 1.33. The swing events are close: US May CPI this week and the 16–17 June FOMC, into rising hike expectations.
Geopolitics & world news
The Middle East swung from escalation back to an uneasy hold. The conflict’s 101st day saw Iran and Israel trade missiles and drones overnight Monday — the first exchange since the early-April ceasefire — sending Brent above $97 before Iran announced a halt that afternoon and Israel refrained at Trump’s request, with Netanyahu accepting. Both sides warn they can resume, and Lebanon is the fault line: Tehran ties any restart to Israeli strikes on Hezbollah, while Netanyahu vows to keep hitting the group. Trump’s claim that he “calls the shots” is being tested as his economy polling slides under the war’s weight. Markets read it through oil: crude gave back most of the spike (WTI ~$91), the Strait of Hormuz stays shut for nearly 100 days, and Bloomberg’s columnists flag both a potential “flood of oil” when it reopens and a record run of supertanker orders.
The US–China tech front widened: the Pentagon accused Alibaba, Baidu and BYD of aiding China’s military, Washington urged NATO allies to use defence budgets to strip out Huawei gear, and Bloomberg framed the EU’s “$2tn Taiwan problem” — Europe often pays the bigger price even when the US sets the agenda. Germany and France pulled the plug on their next-generation fighter project, a blow to European defence integration. For the medical reader, the standout is biosecurity: a Bloomberg Big Take argues funding cuts have left the world exposed to a fast-spreading Ebola strain with no known treatment or vaccine, while a companion piece details why the DR Congo outbreak is proving hard to slow — a direct tie to this week’s clinical desk. On the corporate-health side, GSK is near a >$9bn deal for cancer biotech Nuvalent and AstraZeneca is pushing an obesity pill at the GLP-1 leaders, both signs the drug-development race is accelerating.
Clinical desk · NEJM current issue (4 June 2026)
This week in the New England Journal
A deeper read of the issue’s practice-relevant trials, with the numbers that matter at the bedside. (NEJM publishes weekly on Thursdays, so the 4 June issue remains current today; the next issue lands 11 June.)
Cardiology — LAAC moves toward the anticoagulation-eligible
CHAMPION-AF randomised 3,000 AF patients who were suitable NOAC candidates (mean CHA₂DS₂-VASc 3.5) to a Watchman Flx device or a NOAC. At 3 years the composite of CV death, stroke or systemic embolism was 5.7% vs 4.8% (difference 0.9 pp, 95% CI −0.8 to 2.6) — meeting noninferiority — while non–procedure-related bleeding was roughly halved (10.9% vs 19.0%, HR 0.55), a superiority win. Caveats worth holding onto: strokes were numerically higher with the device (3.6% vs 2.5%; ischaemic stroke/systemic embolism ~0.3%/yr more), the highest-risk patients (CHA₂DS₂-VASc ≥5) were under-represented, only one device was studied, and the trial was industry-funded with an absolute (not relative) noninferiority margin. The companion editorial asks directly whether indications should now widen. Practical read: a stronger case for LAAC as a shared-decision option in bleeding-averse but anticoagulation-eligible AF — the 5-year stroke data will be the tell.
Critical care — high-flow oxygen: fewer intubations, same mortality
SOHO (42 French ICUs, 1,110 patients with P/F ≤200) found day-28 mortality identical at 14.6% vs 14.6% (P=0.98) for high-flow nasal oxygen vs standard oxygen. Intubation by day 28 was lower with high-flow (42.4% vs 48.4%, difference −5.9 pp), but serious events during spontaneous breathing (cardiac arrest or pneumothorax) were numerically more frequent (2.3% vs 1.1%). Read: this tempers the mortality rationale for HFNC; the intubation benefit persists, so the case stays individualised rather than universal.
Oncology — a step-change in pancreatic cancer
Daraxonrasib (RASolute 302). Phase 3, 500 patients with previously treated metastatic PDAC (92% RAS G12); this oral RAS(ON) inhibitor roughly doubled median overall survival vs chemotherapy (13.2 vs 6.6 months, HR 0.40, P<0.001) and improved PFS (7.3 vs 3.5 months, HR 0.45). Grade ≥3 events were actually lower than chemo (61.8% vs 69.6%) and treatment-related discontinuations far lower (1.2% vs 11.2%). In a disease where median survival is under a year, this is the standout result of the issue.
Perioperative apalutamide (PROTEUS). Phase 3, 2,109 patients, ADT ± apalutamide around radical prostatectomy. Pathological complete response / minimal residual disease rose to 8.9% vs 1.0% (OR 10.2) and 5-year metastasis-free survival to 78.2% vs 73.5% (HR 0.80, P=0.02); grade 3/4 events were higher (39.6% vs 31%, mostly rash). The first practice-changing neoadjuvant signal in prostate cancer — though the absolute MFS gain (~4.7 pp) is modest, and the editorial’s “watershed” framing is about direction more than magnitude.
Also: all-oral decitabine–cedazuridine + venetoclax gave complete responses in ~47% of newly diagnosed AML; adjuvant selpercatinib lengthened event-free survival in RET fusion–positive early-stage NSCLC.
AI in the clinic (your beat)
The governance layer is catching up to deployment. A Perspective on ambient AI documentation maps the recording-consent problem — two-party-consent states, where audio is transmitted, and the patchwork of state law that every ambient-scribe pilot now runs into — alongside an NEJM AI review on large language models in informed consent (opportunities vs thin evidence), a privacy analysis of AI scribes, and a behavioural-health letter warning that chatbot empathy can outpace accuracy. Collectively: useful tools, but consent, privacy and monitoring are the gating issues, not raw capability.
Infectious disease — ties to this morning’s Ebola thread
A correspondence characterises the 2025 Sudan virus (an ebolavirus) outbreak in Uganda, and another reports that IV artesunate still performed acceptably in children with partially artemisinin-resistant severe malaria (PfK13 mutations) — reassuring that parenteral artesunate remains usable. Directly relevant context as the markets pages flag a widening DR Congo Ebola outbreak with no known treatment for the strain in circulation.
Briefly noted
Obexelimab cut flares and glucocorticoid use in a phase-3 trial in IgG4-related disease; secukinumab hit its mark in relapsed polymyalgia rheumatica but missed in giant-cell arteritis; dual CAR T-cell desensitisation enabled kidney transplantation in two highly HLA-sensitised candidates; and a clinical-practice review distils what actually moves childhood vaccine hesitancy (clinician recommendation, presumptive framing, empathy).
Read from your open NEJM tab via Control Chrome — the current issue (4 June 2026, still current today; next issue 11 June) plus the full CHAMPION-AF, SOHO, RASolute 302 and PROTEUS abstracts. Figures summarised in original prose under copyright caution — not reproductions, and not medical advice for any individual patient.